Diagnostic Interferon gamma (IFNγ) antibodies (anti-Interferon gamma, anti-IFNγ) and antigens (recombinant Interferon gamma (IFNγ) protein) for Inflammation/autoimmune/inflammatory disease IFNγ detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Product Details
Genemedi produces core diagnostic ingredients for test of Inflammation/autoimmune/inflammatory disease (inflamation, autoimmune disease) and related syndrome. GeneMedi offers paired diagnostics grade Interferon gamma (IFNγ) antibodies (monoclonal antibody, mab) and antigens for Inflammation/autoimmune/inflammatory disease (inflamation, autoimmune disease) rapid test kit of Interferon gamma (IFNγ) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Inflammation/autoimmune/inflammatory disease (inflamation, autoimmune disease ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Interferon gamma?(IFNγ) is a?dimerized?soluble?cytokine?that is the only member of the type II class of?interferons.[1]?The existence of this interferon, which early in its history was known as immune interferon, was described by E. F. Wheelock as a product of human?leukocytes?stimulated with?phytohemagglutinin, and by others as a product of antigen-stimulated?lymphocytes.[2]?It was also shown to be produced in lymphocytes.[3]?or?tuberculin-sensitized mouse?peritoneal?lymphocytes[4]?challenged with?PPD; the resulting?supernatants?were shown to inhibit growth of?vesicular stomatitis virus. Those reports also contained the basic observation underlying the now widely employed?interferon gamma release assay?used to test for?tuberculosis. In humans, the IFNγ protein is encoded by the?IFNG?gene.
Product Description
Cat No. of Pruducts
Product Name
Target
Alias of Target/Biomarker
Expression platform
Isotypes
Bioactivity validation
Tag
Products description
Reconized/Reactive Species
Purity
Application
Formulation
Storage
Cat No. of Pruducts
Product Name
Target
Alias of Target/Biomarker
Expression platform
Isotypes
Bioactivity validation
Tag
Products description
Reconized/Reactive Species
Purity
Application
Formulation
Storage
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.